Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 8881 AL 8895

Validation of the Portuguese version of the Movement Disorder Society non-motor rating scale (MDS-NMS) in Parkinson's disease

Vale TC, Santos DP, Oliveira DS, Paula Brandão PR, Pereira DA, Bouça-Machado R, Silva LO, Mello Rieder CR, Barbosa ER, Cury RG, Parmera JB, Ghizoni Teive HA, Ferreira MG, Ferraz HB, Candeias da Silva C, Tumas V, Nunes Cunha AL, Braga-Neto P, Lima DP, Della Colleta MV, Maia D, de Souza Fontana M, Damas CN, Lobo PP, Rebordão L, Magalhães AD, Peralta AR, Simões RM, Lampreia T, Velon AG, Carneiro D, Raimundo R, Gago M, Mendes A, Chã NV, Damásio J, Costa S, Lopes R, Morgadinho A, Mestre T, Stebbins GT, Luo S, Goetz CG, Ferreira JJ, Cardoso F; MDS-NMS Portuguese Validation Study Group.

Parkinsonism Relat Disord. 2025 Mar;132:107276. doi: 10.1016/j.parkreldis.2025.107276. Epub 2025 Jan 13.

Canadian Association of Radiologists Central Nervous System Diagnostic Imaging Referral Guideline

Hamel C, Avard B, Dea N, Margau R, Mattar A, Michaud A, Schmidt M, Volders D, Witiw C, Worrall J, Murphy A.

Can Assoc Radiol J. 2025 Aug;76(3):435-443. doi: 10.1177/08465371241311247. Epub 2025 Jan 30.

Re-examining the pathobiological basis of gait dysfunction in Parkinson's disease

Cho N, Kalia LV, Kalia SK.

Trends Neurosci. 2025 Mar;48(3):189-199. doi: 10.1016/j.tins.2025.01.002. Epub 2025 Jan 29.

Retrospective database analysis on the demographics and resource utilization of patients with Parkinson's disease in Quebec, Canada

Baribeau V, Mohammed S, Awan A, Parison D, Lachaine J.

Clin Park Relat Disord. 2025 Jan 12;12:100300. doi: 10.1016/j.prdoa.2025.100300. eCollection 2025.

The basics of PET molecular imaging in neurodegenerative disorders with dementia and/or parkinsonism

Bronte A, Prieto E, Quincoces G, Erro E, Arbizu J.

Eur Radiol. 2025 Aug;35(8):4621-4634. doi: 10.1007/s00330-025-11388-5. Epub 2025 Feb 6.

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J, Duncan G, Power K, Gallen S, Kerr J, Chaudhuri KR, Batzu L, Rota S, Jabbari E, Morris H, Limousin P, Greig N, Li Y, Libri V, Gandhi S, Athauda D, Chowdhury K, Foltynie T.

Lancet. 2025 Feb 22;405(10479):627-636. doi: 10.1016/S0140-6736(24)02808-3. Epub 2025 Feb 4.

Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review

Rossi M, Schaake S, Usnich T, Boehm J, Steffen N, Schell N, Krüger C, Gül-Demirkale T, Bahr N, Kleinz T, Madoev H, Laabs BH, Gan-Or Z, Alcalay RN, Lohmann K, Klein C.

Mov Disord. 2025 Apr;40(4):605-618. doi: 10.1002/mds.30141. Epub 2025 Feb 10.

Impact of pharmacist-physician collaboration on patient outcomes in Parkinson's disease: a randomised controlled trial in tertiary care

Techa-Angkoon P, Pitakpatapee Y, Saengphatrachai W, Srivanitchapoom P, Suansanae T.

Int J Clin Pharm. 2025 Jun;47(3):834-843. doi: 10.1007/s11096-025-01883-6. Epub 2025 Feb 13.

Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies

Devos D, Rascol O, Meissner WG, Foubert-Samier A, Lewis S, Tranchant C, Anheim M, Maltête D, Remy P, Eggert K, Pape H, Geny C, Couratier P, Carroll C, Sheridan R, Burn D, Pavese N, Raw J, Berg D, Suchowersky O, Kalia LV, Evans A, Drapier S, Danaila T, Schnitzler A, Corvol JC, Defer G, Temin NT, Fradette C, Tricta F, Moreau C; a Parkinson's disease study group.

J Parkinsons Dis. 2025 Feb;15(1):72-86. doi: 10.1177/1877718X241300295. Epub 2024 Dec 27.

Aging, cellular senescence and Parkinson's disease

Ma Y, Erb ML, Moore DJ.

J Parkinsons Dis. 2025 Mar;15(2):239-254. doi: 10.1177/1877718X251316552. Epub 2025 Feb 2.

Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial

Ferreira JJ, Gago MF, Costa R, Fonseca MM, Almeida J, Rocha JF, Holenz J, Trenkwalder C.

J Parkinsons Dis. 2025 Feb;15(1):87-96. doi: 10.1177/1877718X241306711. Epub 2025 Jan 17.

Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation

Xu J, Xu X, Guo X, Li Z, Dong B, Qi C, Yang C, Zhou D, Wang J, Song L, He P, Kong S, Zheng S, Fu S, Xie W, Liu X, Cao Y, Liu Y, Qiu Y, Zheng Z, Yang F, Gan J, Wu X.

J Parkinsons Dis. 2025 Mar;15(2):349-360. doi: 10.1177/1877718X241312605. Epub 2025 Feb 13.

Cross-evaluation of wearable data for use in Parkinson's disease research: a free-living observational study on Empatica E4, Fitbit Sense, and Oura

Reithe H, Marty B, Torrado JC, Førsund E, Husebo BS, Erdal A, Kverneng SU, Sheard E, Tzoulis C, Patrascu M.

Biomed Eng Online. 2025 Feb 21;24(1):22. doi: 10.1186/s12938-025-01353-0.

Dysregulation of serotonergic neurotransmission in Parkinson disease: A key duet

Khowdiary MM, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Elhenawy AA, Babalghith AO, Shokr MM, Alexiou A, Papadakis M, El-Saber Batiha G.

Eur J Pharmacol. 2025 May 15;995:177419. doi: 10.1016/j.ejphar.2025.177419. Epub 2025 Feb 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias